In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Featured Stories

Clinicians: ‘Show Me The Impact And Outcomes Of AI Tools’

Royal Philips’ ninth annual Future Health Index global report reveals a growing acceptance by clinicians and health care stakeholders of virtual care and AI-enabled innovation. These tools can address workforce shortages, financial burdens and growing demand for care, said chief innovation and strategy officer Shez Partovi.

Leadership Artificial Intelligence

A GenAI Copilot For The Regulatory Affairs Team

A GenAI copilot for biopharma regulatory requirements could yield significant returns.

BIO Roundup: Deal-Making Tips And Tricks

Key insights from the recent the BIO International Convention in San Diego, US.

Data Spotlight

Deals in Depth: May 2024

Six $1bn+ alliances were penned in May. In the top alliance by deal value, AC Immune SA granted Takeda an option to license exclusive global rights to active immunotherapies targeting toxic forms of amyloid beta, including ACI-24.060 for the treatment of Alzheimer’s disease. AC Immune will receive $100m up front and is eligible to receive an option exercise fee and additional potential development, commercial and sales-based milestones of up to approximately $2.1bn, plus sales royalties.

Deals Shaping The Industry, May 2024

An interactive look at pharma, medtech and diagnostics deals made during May 2024. Data courtesy of Biomedtracker.

Executives On The Move: May 2024

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

‘Pharma Is Not Just A Cost Component’ – Showcasing Value As Well As Innovation

Astellas Pharma’s chief commercial officer discusses the biopharma industry’s responsibility to drive change in health care.

See All
Growth

BIO Roundup: Deal-Making Tips And Tricks

Key insights from the recent the BIO International Convention in San Diego, US.

Women’s Health Innovation: What Are We Waiting For?

An investigator, an investor and an inventor walk into the New York Stock Exchange, and it’s no joke. Women’s health is a fruitful investment with a clear path to financial return. 

Entering Estonia: To Build Bigger Castles, You Need A Better Sandbox

Estonia is hoping to  create a brighter future by attracting leading startups to its borders, a process that will bring tax revenues, jobs and infrastructure.

BioBytes: AI-Related Deals In Q1 2024

BioBytes presents an overview of AI-related deals in Q1 2024. This is the first in a recurring series of quarterly deal updates.   

See All
Innovation

ASCO 2024 In Review: A Webinar With Citeline Analysts

Citeline analysts offered deep dives into some of the data presented at the American Society of Clinical Oncology annual meeting, including both major highlights and some lesser-known finds. 

‘A New Era’: What Next For CRISPR Gene Editing After First Approval?

Emerging out of a landmark 2023, CRISPR companies and researchers are pushing in vivo therapies and other approaches closer to the clinic and potential approval.

What Pandemic? Clinical Trials Shake The COVID-19 Dust Off Their Feet

Industry-sponsored clinical trial activity has returned to pre-pandemic trends now that the turmoil of COVID-19 has abated, finds a new report from Citeline.

How Debiopharm’s Licensing Model Bridges The Biotech And Pharma Gap

Sandra von Meier, head of business development and licensing at Debiopharm explains how the company’s distinctive licensing business model is helping bring new drugs to market.

See All
Leadership

Clinicians: ‘Show Me The Impact And Outcomes Of AI Tools’

Royal Philips’ ninth annual Future Health Index global report reveals a growing acceptance by clinicians and health care stakeholders of virtual care and AI-enabled innovation. These tools can address workforce shortages, financial burdens and growing demand for care, said chief innovation and strategy officer Shez Partovi.

Executives On The Move: May 2024

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

AI-Driven CHARM’s Number One Goal: Transitioning To A Clinical-Stage Biotech

Laksh Aithani, CEO of CHARM Therapeutics, discusses key challenges for the flourishing AI drug development sector including finding the right people and the need for more success stories.

Execs On The Move: April 2024

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

See All
Market Access

A GenAI Copilot For The Regulatory Affairs Team

A GenAI copilot for biopharma regulatory requirements could yield significant returns.

16 Key Trends Reshaping The Future Of Medtech

Record attendance at the 2024 MedTech Forum in Vienna heard industry leaders voice optimism grounded in realism about future developments for Europe’s medtech industry, markets and delivery of care to patients. In Vivo filtered out 16 trends to watch.

Moving Towards A Total Lifecycle Regulatory Approach For AI Devices

Proportionately regulating highly adaptive AI as a medical device can be done with predetermined change control plans. The US, UK and Canada are advancing the concept, as Ropes & Gray and the US FDA explained.

Greater Bay Area Device Adoption Can Be A Steppingstone To China Uptake

Medical devices selected for use in the Guangdong-Hong Kong-Macao Greater Bay Area may potentially be fast-tracked for adoption across mainland China, according to a new industry white paper.

See All
Market Intelligence

Deals in Depth: May 2024

Six $1bn+ alliances were penned in May. In the top alliance by deal value, AC Immune SA granted Takeda an option to license exclusive global rights to active immunotherapies targeting toxic forms of amyloid beta, including ACI-24.060 for the treatment of Alzheimer’s disease. AC Immune will receive $100m up front and is eligible to receive an option exercise fee and additional potential development, commercial and sales-based milestones of up to approximately $2.1bn, plus sales royalties.

Biopharma Market’s Green Shoots Are Evident But Full Recovery Must Wait Awhile

Biopharma markets may follow the downward trajectory of tech during tough times, but they also chase it back up the value curve. Recovery is just a matter of time, says Seventure’s Isabelle de Crémoux in this commentary on investment trends, the financial markets and the VC environment.

Gene Therapy’s Next Target: Our Microbes

CRISPR pioneer Jennifer Doudna recently co-launched an initiative focused on microbial gene editing, but French biotech Eligo has been diligently working on this for 10 years. 

Deals Shaping The Industry, May 2024

An interactive look at pharma, medtech and diagnostics deals made during May 2024. Data courtesy of Biomedtracker.

See All
Recent Stories

ASCO 2024 In Review: A Webinar With Citeline Analysts

Citeline analysts offered deep dives into some of the data presented at the American Society of Clinical Oncology annual meeting, including both major highlights and some lesser-known finds. 

‘A New Era’: What Next For CRISPR Gene Editing After First Approval?

Emerging out of a landmark 2023, CRISPR companies and researchers are pushing in vivo therapies and other approaches closer to the clinic and potential approval.

What Pandemic? Clinical Trials Shake The COVID-19 Dust Off Their Feet

Industry-sponsored clinical trial activity has returned to pre-pandemic trends now that the turmoil of COVID-19 has abated, finds a new report from Citeline.

Deals in Depth: May 2024

Six $1bn+ alliances were penned in May. In the top alliance by deal value, AC Immune SA granted Takeda an option to license exclusive global rights to active immunotherapies targeting toxic forms of amyloid beta, including ACI-24.060 for the treatment of Alzheimer’s disease. AC Immune will receive $100m up front and is eligible to receive an option exercise fee and additional potential development, commercial and sales-based milestones of up to approximately $2.1bn, plus sales royalties.

Clinicians: ‘Show Me The Impact And Outcomes Of AI Tools’

Royal Philips’ ninth annual Future Health Index global report reveals a growing acceptance by clinicians and health care stakeholders of virtual care and AI-enabled innovation. These tools can address workforce shortages, financial burdens and growing demand for care, said chief innovation and strategy officer Shez Partovi.

Biopharma Market’s Green Shoots Are Evident But Full Recovery Must Wait Awhile

Biopharma markets may follow the downward trajectory of tech during tough times, but they also chase it back up the value curve. Recovery is just a matter of time, says Seventure’s Isabelle de Crémoux in this commentary on investment trends, the financial markets and the VC environment.

How Debiopharm’s Licensing Model Bridges The Biotech And Pharma Gap

Sandra von Meier, head of business development and licensing at Debiopharm explains how the company’s distinctive licensing business model is helping bring new drugs to market.

Gene Therapy’s Next Target: Our Microbes

CRISPR pioneer Jennifer Doudna recently co-launched an initiative focused on microbial gene editing, but French biotech Eligo has been diligently working on this for 10 years. 

Deals Shaping The Industry, May 2024

An interactive look at pharma, medtech and diagnostics deals made during May 2024. Data courtesy of Biomedtracker.

ASCO Roundup: Looking For The Future Of Cancer Research

As the American Society of Clinical Oncology annual meeting drew to a close, industry execs discussed staying competitive, adjusting to policy changes and how artificial intelligence is advancing cancer R&D.

Executives On The Move: May 2024

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

16 Key Trends Reshaping The Future Of Medtech

Record attendance at the 2024 MedTech Forum in Vienna heard industry leaders voice optimism grounded in realism about future developments for Europe’s medtech industry, markets and delivery of care to patients. In Vivo filtered out 16 trends to watch.

UsernamePublicRestriction

Register